20.83 USD
+0.63 (+3.12%)
20.83 USD
0 (0%)
We assign a fundamental rating of 6 out of 10 to CDNA. CDNA was compared to 525 industry peers in the Biotechnology industry. CDNA has an excellent financial health rating, but there are some minor concerns on its profitability. CDNA is growing strongly while it is still valued neutral. This is a good combination!
1. Profitability
1.1 Basic Checks
- In the past year CDNA was profitable.
- In the past year CDNA had a positive cash flow from operations.
- CDNA had negative earnings in 4 of the past 5 years.
- The reported operating cash flow has been mixed in the past 5 years: CDNA reported negative operating cash flow in multiple years.
1.2 Ratios
- The Return On Assets of CDNA (14.06%) is better than 95.05% of its industry peers.
- CDNA has a Return On Equity of 19.53%. This is amongst the best in the industry. CDNA outperforms 95.81% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 14.06% | ||
| ROE | 19.53% | ||
| ROIC | N/A |
ROA(3y)-14.72%
ROA(5y)-10.93%
ROE(3y)-25.57%
ROE(5y)-18.01%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- CDNA's Profit Margin of 16.97% is amongst the best of the industry. CDNA outperforms 92.95% of its industry peers.
- The Gross Margin of CDNA (67.62%) is better than 80.76% of its industry peers.
- CDNA's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | 16.97% | ||
| GM | 67.62% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.01%
GM growth 5Y0.9%
2. Health
2.1 Basic Checks
- CDNA does not have a ROIC to compare to the WACC, probably because it is not profitable.
- CDNA has more shares outstanding than it did 1 year ago.
- The number of shares outstanding for CDNA has been increased compared to 5 years ago.
- There is no outstanding debt for CDNA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
- An Altman-Z score of 3.92 indicates that CDNA is not in any danger for bankruptcy at the moment.
- The Altman-Z score of CDNA (3.92) is better than 70.86% of its industry peers.
- There is no outstanding debt for CDNA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 3.92 |
ROIC/WACCN/A
WACC8.94%
2.3 Liquidity
- CDNA has a Current Ratio of 3.03. This indicates that CDNA is financially healthy and has no problem in meeting its short term obligations.
- CDNA has a Current ratio of 3.03. This is in the lower half of the industry: CDNA underperforms 63.62% of its industry peers.
- A Quick Ratio of 2.75 indicates that CDNA has no problem at all paying its short term obligations.
- CDNA has a Quick ratio of 2.75. This is in the lower half of the industry: CDNA underperforms 65.33% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.03 | ||
| Quick Ratio | 2.75 |
3. Growth
3.1 Past
- CDNA shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 242.11%, which is quite impressive.
- CDNA shows a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 37.47% yearly.
- The Revenue has grown by 14.46% in the past year. This is quite good.
- CDNA shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 21.30% yearly.
EPS 1Y (TTM)242.11%
EPS 3Y23.03%
EPS 5Y37.47%
EPS Q2Q%100%
Revenue 1Y (TTM)14.46%
Revenue growth 3Y4.04%
Revenue growth 5Y21.3%
Sales Q2Q%20.72%
3.2 Future
- Based on estimates for the next years, CDNA will show a very strong growth in Earnings Per Share. The EPS will grow by 38.18% on average per year.
- The Revenue is expected to grow by 13.01% on average over the next years. This is quite good.
EPS Next Y25.04%
EPS Next 2Y29.46%
EPS Next 3Y31.86%
EPS Next 5Y38.18%
Revenue Next Year13.06%
Revenue Next 2Y12.2%
Revenue Next 3Y11.7%
Revenue Next 5Y13.01%
3.3 Evolution
- When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
- Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
- Based on the Price/Earnings ratio of 32.05, the valuation of CDNA can be described as expensive.
- Based on the Price/Earnings ratio, CDNA is valued cheaply inside the industry as 93.14% of the companies are valued more expensively.
- CDNA's Price/Earnings ratio indicates a similar valuation than the S&P500 average which is at 27.32.
- A Price/Forward Earnings ratio of 23.02 indicates a rather expensive valuation of CDNA.
- Compared to the rest of the industry, the Price/Forward Earnings ratio of CDNA indicates a rather cheap valuation: CDNA is cheaper than 92.76% of the companies listed in the same industry.
- When comparing the Price/Forward Earnings ratio of CDNA to the average of the S&P500 Index (24.30), we can say CDNA is valued inline with the index average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 32.05 | ||
| Fwd PE | 23.02 |
4.2 Price Multiples
- CDNA's Price/Free Cash Flow ratio is rather cheap when compared to the industry. CDNA is cheaper than 94.29% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 29.42 | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
- CDNA's PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
- CDNA's earnings are expected to grow with 31.86% in the coming years. This may justify a more expensive valuation.
PEG (NY)1.28
PEG (5Y)0.86
EPS Next 2Y29.46%
EPS Next 3Y31.86%
5. Dividend
5.1 Amount
- No dividends for CDNA!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
20.83
+0.63 (+3.12%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-04 2025-11-04/amc
Earnings (Next)02-24 2026-02-24/amc
Inst Owners102.35%
Inst Owner Change0.65%
Ins Owners2.48%
Ins Owner Change0.78%
Market Cap1.07B
Revenue(TTM)358.00M
Net Income(TTM)60.76M
Analysts80
Price Target24.48 (17.52%)
Short Float %11.91%
Short Ratio6.44
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)37.85%
Min EPS beat(2)-18.08%
Max EPS beat(2)93.77%
EPS beat(4)3
Avg EPS beat(4)37.25%
Min EPS beat(4)-18.08%
Max EPS beat(4)93.77%
EPS beat(8)7
Avg EPS beat(8)226.86%
EPS beat(12)11
Avg EPS beat(12)161.16%
EPS beat(16)12
Avg EPS beat(16)102.04%
Revenue beat(2)1
Avg Revenue beat(2)-1.62%
Min Revenue beat(2)-6.22%
Max Revenue beat(2)2.98%
Revenue beat(4)2
Avg Revenue beat(4)-0.98%
Min Revenue beat(4)-6.22%
Max Revenue beat(4)2.98%
Revenue beat(8)6
Avg Revenue beat(8)5.39%
Revenue beat(12)8
Avg Revenue beat(12)5.96%
Revenue beat(16)8
Avg Revenue beat(16)3.77%
PT rev (1m)4.35%
PT rev (3m)6.67%
EPS NQ rev (1m)9.13%
EPS NQ rev (3m)16.65%
EPS NY rev (1m)0%
EPS NY rev (3m)23.74%
Revenue NQ rev (1m)0.73%
Revenue NQ rev (3m)0.89%
Revenue NY rev (1m)0.32%
Revenue NY rev (3m)1.55%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 32.05 | ||
| Fwd PE | 23.02 | ||
| P/S | 2.99 | ||
| P/FCF | 29.42 | ||
| P/OCF | 25.17 | ||
| P/B | 3.44 | ||
| P/tB | 4.51 | ||
| EV/EBITDA | N/A |
EPS(TTM)0.65
EY3.12%
EPS(NY)0.91
Fwd EY4.34%
FCF(TTM)0.71
FCFY3.4%
OCF(TTM)0.83
OCFY3.97%
SpS6.96
BVpS6.05
TBVpS4.62
PEG (NY)1.28
PEG (5Y)0.86
Graham Number9.41
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 14.06% | ||
| ROE | 19.53% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | 16.97% | ||
| GM | 67.62% | ||
| FCFM | 10.17% |
ROA(3y)-14.72%
ROA(5y)-10.93%
ROE(3y)-25.57%
ROE(5y)-18.01%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.01%
GM growth 5Y0.9%
F-Score7
Asset Turnover0.83
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 42.35% | ||
| Cap/Sales | 1.71% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | 59.94% | ||
| Current Ratio | 3.03 | ||
| Quick Ratio | 2.75 | ||
| Altman-Z | 3.92 |
F-Score7
WACC8.94%
ROIC/WACCN/A
Cap/Depr(3y)106.55%
Cap/Depr(5y)139.53%
Cap/Sales(3y)4.27%
Cap/Sales(5y)5%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)242.11%
EPS 3Y23.03%
EPS 5Y37.47%
EPS Q2Q%100%
EPS Next Y25.04%
EPS Next 2Y29.46%
EPS Next 3Y31.86%
EPS Next 5Y38.18%
Revenue 1Y (TTM)14.46%
Revenue growth 3Y4.04%
Revenue growth 5Y21.3%
Sales Q2Q%20.72%
Revenue Next Year13.06%
Revenue Next 2Y12.2%
Revenue Next 3Y11.7%
Revenue Next 5Y13.01%
EBIT growth 1Y37.2%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year156.58%
EBIT Next 3Y71.37%
EBIT Next 5Y67.07%
FCF growth 1Y364.87%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y1603.82%
OCF growth 3YN/A
OCF growth 5YN/A
CAREDX INC / CDNA FAQ
What is the ChartMill fundamental rating of CAREDX INC (CDNA) stock?
ChartMill assigns a fundamental rating of 6 / 10 to CDNA.
What is the valuation status of CAREDX INC (CDNA) stock?
ChartMill assigns a valuation rating of 5 / 10 to CAREDX INC (CDNA). This can be considered as Fairly Valued.
What is the profitability of CDNA stock?
CAREDX INC (CDNA) has a profitability rating of 4 / 10.
What are the PE and PB ratios of CAREDX INC (CDNA) stock?
The Price/Earnings (PE) ratio for CAREDX INC (CDNA) is 32.05 and the Price/Book (PB) ratio is 3.44.
Can you provide the financial health for CDNA stock?
The financial health rating of CAREDX INC (CDNA) is 7 / 10.